These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19554599)

  • 21. Correlation between energetics of collisionally activated decompositions, interaction energy and biological potency of carbamate FAAH inhibitors.
    Valitutti G; Duranti A; Lodola A; Mor M; Piersanti G; Piomelli D; Rivara S; Tontini A; Tarzia G; Traldi P
    J Mass Spectrom; 2007 Dec; 42(12):1624-7. PubMed ID: 18085570
    [No Abstract]   [Full Text] [Related]  

  • 22. Design, synthesis, and in vitro evaluation of carbamate derivatives of 2-benzoxazolyl- and 2-benzothiazolyl-(3-hydroxyphenyl)-methanones as novel fatty acid amide hydrolase inhibitors.
    Myllymäki MJ; Saario SM; Kataja AO; Castillo-Melendez JA; Nevalainen T; Juvonen RO; Järvinen T; Koskinen AM
    J Med Chem; 2007 Aug; 50(17):4236-42. PubMed ID: 17665899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
    Ahn K; Johnson DS; Fitzgerald LR; Liimatta M; Arendse A; Stevenson T; Lund ET; Nugent RA; Nomanbhoy TK; Alexander JP; Cravatt BF
    Biochemistry; 2007 Nov; 46(45):13019-30. PubMed ID: 17949010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system.
    Gattinoni S; De Simone C; Dallavalle S; Fezza F; Nannei R; Amadio D; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
    ChemMedChem; 2010 Mar; 5(3):357-60. PubMed ID: 20112328
    [No Abstract]   [Full Text] [Related]  

  • 25. Hexafluoroisopropyl Carbamates as Selective MAGL and Dual MAGL/FAAH Inhibitors: Biochemical and Physicochemical Properties.
    Barth M; Rudolph S; Kampschulze J; Meyer Zu Vilsendorf I; Hanekamp W; Mulac D; Langer K; Lehr M
    ChemMedChem; 2022 May; 17(9):e202100757. PubMed ID: 35072346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of carbamate derivatives as fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
    Jaiswal S; Gupta G; Ayyannan SR
    Arch Pharm (Weinheim); 2022 Nov; 355(11):e2200081. PubMed ID: 35924298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
    Zhang D; Saraf A; Kolasa T; Bhatia P; Zheng GZ; Patel M; Lannoye GS; Richardson P; Stewart A; Rogers JC; Brioni JD; Surowy CS
    Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats.
    Pędzińska-Betiuk A; Weresa J; Toczek M; Baranowska-Kuczko M; Kasacka I; Harasim-Symbor E; Malinowska B
    Br J Pharmacol; 2017 Jul; 174(13):2114-2129. PubMed ID: 28437860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
    Moreno-Sanz G; Duranti A; Melzig L; Fiorelli C; Ruda GF; Colombano G; Mestichelli P; Sanchini S; Tontini A; Mor M; Bandiera T; Scarpelli R; Tarzia G; Piomelli D
    J Med Chem; 2013 Jul; 56(14):5917-30. PubMed ID: 23822179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH.
    Paylor B; Holt S; Fowler CJ
    Pharmacol Res; 2006 Dec; 54(6):481-5. PubMed ID: 16997568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-aryl 2-aryloxyacetamides as a new class of fatty acid amide hydrolase (FAAH) inhibitors.
    Sunduru N; Svensson M; Cipriano M; Marwaha S; Andersson CD; Svensson R; Fowler CJ; Elofsson M
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):513-521. PubMed ID: 28114819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and interaction fields.
    Myllymäki MJ; Käsnänen H; Kataja AO; Lahtela-Kakkonen M; Saario SM; Poso A; Koskinen AM
    Eur J Med Chem; 2009 Oct; 44(10):4179-91. PubMed ID: 19539407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Uracil Derivatives as Potent Inhibitors of Fatty Acid Amide Hydrolase.
    Qiu Y; Zhang Y; Li Y; Ren J
    Molecules; 2016 Feb; 21(2):. PubMed ID: 26901181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 1-Heteroarylpropan-2-ones as inhibitors of fatty acid amide hydrolase: Studies on structure-activity relationships and metabolic stability.
    Zahov S; Garzinsky D; Hanekamp W; Lehr M
    Bioorg Med Chem; 2017 Feb; 25(3):825-837. PubMed ID: 27989417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxime carbamate--discovery of a series of novel FAAH inhibitors.
    Sit SY; Conway CM; Xie K; Bertekap R; Bourin C; Burris KD
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1272-7. PubMed ID: 20036536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates.
    Chang JW; Niphakis MJ; Lum KM; Cognetta AB; Wang C; Matthews ML; Niessen S; Buczynski MW; Parsons LH; Cravatt BF
    Chem Biol; 2012 May; 19(5):579-88. PubMed ID: 22542104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
    Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
    J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fatty acid amide hydrolase inhibitor (URB597) as a regulator of myocardial lipid metabolism in spontaneously hypertensive rats.
    Harasim-Symbor E; Polak A; Pędzińska-Betiuk A; Weresa J; Malinowska B; Lewandowska A; Kasacka I; Chabowski A
    Chem Phys Lipids; 2019 Jan; 218():141-148. PubMed ID: 30578756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel propanamides as fatty acid amide hydrolase inhibitors.
    Deplano A; Morgillo CM; Demurtas M; Björklund E; Cipriano M; Svensson M; Hashemian S; Smaldone G; Pedone E; Luque FJ; Cabiddu MG; Novellino E; Fowler CJ; Catalanotti B; Onnis V
    Eur J Med Chem; 2017 Aug; 136():523-542. PubMed ID: 28535469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.